A Phase 1 Open-Label Mass Balance clinical trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants.

2024-515556-20-00 Protocol TV56286-MB-10193 Human pharmacology (Phase I) - Other Ended

Start 7 Oct 2024 · End 29 Nov 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol TV56286-MB-10193

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 8
Countries 1
Sites 1

Healthy participant

Key facts

Sponsor
Teva Branded Pharmaceutical Products R&D Inc.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
7 Oct 2024 → 29 Nov 2024
Decision date (initial)
2024-10-04
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy participant

VersionLevelCodeTermSystem organ class
21.1 PT 10064060 Multiple system atrophy 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Teva Branded Pharmaceutical Products R&D Inc.

Sponsor organisation
Teva Branded Pharmaceutical Products R&D Inc.
Address
145 Brandywine Parkway
City
West Chester
Postcode
19380-4245
Country
United States

Scientific contact point

Organisation
Teva Branded Pharmaceutical Products R&D Inc.
Contact name
Medical Information

Public contact point

Organisation
Teva Branded Pharmaceutical Products R&D Inc.
Contact name
Medical Information

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 8 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-10-07 2024-11-29 2024-10-08 2024-10-15

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-19 Netherlands Acceptable
2024-10-04
2024-10-04